Get the Stockscreener App
153.87
0.42%
0.65
After Hours:
153.87
Krystal Biotech Inc stock is traded at $153.87, with a volume of 360.33K.
It is up +0.42% in the last 24 hours and up +11.94% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$153.22
Open:
$151.63
24h Volume:
360.33K
Relative Volume:
1.01
Market Cap:
$4.45B
Revenue:
$290.51M
Net Income/Loss:
$89.16M
P/E Ratio:
51.46
EPS:
2.99
Net Cash Flow:
$119.18M
1W Performance:
+2.58%
1M Performance:
+11.94%
6M Performance:
-3.67%
1Y Performance:
-26.19%
1-Day Range:
$151.00
$157.00
1-Week Range:
$147.35
$157.00
52-Week Range:
$122.80
$209.07
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
153.87 | 4.43B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
How does Krystal Biotech Inc. compare to its industry peersEarnings Report Growth Plan For Smart Trading - jammulinksnews.com
Why is Krystal Biotech Inc. stock attracting strong analyst attentionAI Powered Growth Plan From AI Tools - jammulinksnews.com
Quantitative breakdown of Krystal Biotech Inc. recent moveAlpha Driven Watchlist With Alerts Published - metal.it
How Krystal Biotech Inc. stock performs during market volatilityTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Why Krystal Biotech Inc. stock attracts strong analyst attentionWeekly Chart Analysis With Entry Advice Provided - metal.it
Why We're Not Concerned About Krystal Biotech, Inc.'s (NASDAQ:KRYS) Share Price - 富途牛牛
Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025 - The Manila Times
Will Krystal Biotech Inc. Recover After Recent DeclineIntraday Trend Analysis for Fast Gains Released - metal.it
What is the risk reward ratio of investing in Krystal Biotech Inc. stockAdvanced Screener Guidance With High Returns - jammulinksnews.com
Krystal Biotech receives regulatory approval to expand to Japan - The Business Journals
Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth - Yahoo Finance
Krystal Biotech’s Vyjuvek authorised in Japan to treat DEB - World Pharmaceutical Frontiers
What is the dividend policy of Krystal Biotech Inc. stockUnlock your portfolio’s hidden potential - jammulinksnews.com
How volatile is Krystal Biotech Inc. stock compared to the marketFree Stock Chart Pattern Guide - jammulinksnews.com
What catalysts could drive Krystal Biotech Inc. stock higher in 2025Post Market Outlook For Smart Trading - jammulinksnews.com
What makes Krystal Biotech Inc. stock price move sharplyUnlock exclusive stock market forecasts - jammulinksnews.com
Is Krystal Biotech Inc. stock overvalued or undervaluedUnlock your portfolio’s full growth potential - jammulinksnews.com
Krystal Biotech Retains 'Buy' Rating with $219 Price Target - AInvest
Krystal Biotech’s Subsidiary Reports Positive Phase 1 Results - The Globe and Mail
A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $192 to $240 - 富途牛牛
Krystal Biotech (KRYS) Retains 'Buy' Rating with $219 Price Targ - GuruFocus
What analysts say about Krystal Biotech Inc. stockSuperior returns - PrintWeekIndia
Positive Phase 1 Trial Results for KB304 Bolster Buy Rating for Krystal Biotech Amidst Promising Market Potential - TipRanks
Krystal Biotech Gains Approval for DEB Treatment in Japan - TipRanks
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa - The Manila Times
Krystal Biotech's VYJUVEK Receives Approval in Japan for Dystrophic Epidermolysis Bullosa Treatment from Birth - Quiver Quantitative
Is Krystal Biotech Inc. a good long term investmentFree Predictions - PrintWeekIndia
Revolutionary Genetic Treatment for Rare Skin Disease Gets Historic Japan Approval with Home Use Option - Stock Titan
What risks could impact Krystal Biotech Inc. stock performanceTremendous gains - jammulinksnews.com
Krystal Biotech’s Promising Aesthetic Developments and Positive Phase I Results Justify Buy Rating - TipRanks
What drives Krystal Biotech Inc. stock priceFree Wealth Management Insights - PrintWeekIndia
Jeune Announces Positive Results and Significant Aesthetic - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS), Abivax SA Sponsored ADR (ABVX) and Kyowa Kirin Co (OtherKYKOF) - The Globe and Mail
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté - GlobeNewswire
Phase 1 Trial Shows 100% Success Rate for Novel Décolleté Wrinkle Treatment | KRYS Stock News - Stock Titan
Krystal Biotech Inc. Stock Analysis and ForecastFree Stock Movement Tracking - jammulinksnews.com
Krystal Biotech (KRYS) Gets a Buy from Bank of America Securities - The Globe and Mail
Krystal Biotech price target lowered to $192 from $193 at BofA - TipRanks
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):